Investigational drug · Phase 3
L19TNF
Also called: L19IL2, Onfekafusp, Daromun, bifikafusp
Not approved by FDA. In 10 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Glioblastoma, Locally Advanced Basal Cell Carcinoma, Melanoma Stage III.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
10
10 still active
All registered trials
19
Any phase or sponsor naming "L19TNF"
First trial start
2016
Jul 1, 2016
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "L19TNF", any sponsor or status.
- Phase 214
Conditions studied
As listed on its trial records.
- Glioblastoma
- Locally Advanced Basal Cell Carcinoma
- Melanoma Stage III
- Melanoma Stage IV
- Melanoma Stage IIIB
- Melanoma Stage IIIC
- Melanoma Stage IIID
- Locally Advanced Cutaneous Squamous Cell Carcinoma
- Malignant Melanoma
- Soft Tissue Sarcoma
Approved drugs for the same conditions: Melanoma · Brain tumors (glioma) · Sarcoma · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "L19TNF" as an intervention, largest first.
Philogen S.p.A.Industry
NCT04443010 · 226 participants (planned) · Start Jan 20, 2021 · Primary completion Oct 2026
Drug: Onfekafusp alfa; Temozolomide · For: Glioblastoma
Sites: Zurich, Switzerland
- Neoadjuvant L19IL2/L19TNF- Pivotal StudyPivotal-lookingActive, not recruiting
Philogen S.p.A.Industry
NCT02938299 · 214 participants (planned) · Start Jul 1, 2016 · Primary completion Oct 2024
Drug: L19IL2 + L19TNF · For: Malignant Melanoma
Sites: Marseille, France; Nantes, France; Villejuif, France · 22 sites in all
- Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma PatientsPivotal-lookingRecruiting
Philogen S.p.A.Industry
NCT03567889 · 186 participants (planned) · Start Sep 20, 2018 · Primary completion Dec 2027
Drug: Daromun; Adjuvant therapy · For: Melanoma Stage IIIB; Melanoma Stage IIIC; Melanoma Stage IIID
Sites: Phoenix, Arizona; La Jolla, California; Orange, California · 37 sites in all
- L19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC)Pivotal-lookingRecruiting
Philogen S.p.A.Industry
NCT07227350 · 180 participants (planned) · Start Sep 28, 2026 · Primary completion Feb 2031
Drug: L19IL2; L19TNF and 1 more · For: Locally Advanced Basal Cell Carcinoma
Sites: Tampa, Florida; Atlanta, Georgia; Durham, North Carolina · 18 sites in all
- Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination With Pembrolizumab, in Unresectable Melanoma PatientsPivotal-lookingRecruiting
Philogen S.p.A.Industry
NCT06284590 · 162 participants (planned) · Start Jul 12, 2024 · Primary completion Jul 2028
Drug: L19IL2; L19TNF and 2 more · For: Melanoma Stage III; Melanoma Stage IV
Sites: Hartford, Connecticut; New York, New York; Essen, Germany · 7 sites in all
- A Study to Evaluate Safety and Efficacy of L19TNF Plus Lomustine in Patients With Glioblastoma at First ProgressionPivotal-lookingStatus unknown
Philogen S.p.A.Industry
NCT04573192 · 142 participants (planned) · Start Feb 19, 2021 · Primary completion Mar 2025
Drug: L19TNF; Lomustine · For: Glioblastoma
Sites: Bron, France; Paris, France; Bonn, Germany · 15 sites in all
- Treatment of Metastatic Soft Tissue Sarcoma (STS) Patients (FIBROSARC USA)Pivotal-lookingStatus unknown
Philogen S.p.A.Industry
NCT03420014 · 114 participants (planned) · Start Dec 27, 2018 · Primary completion Dec 2024
Drug: Doxorubicin · For: Leiomyosarcoma
Sites: Phoenix, Arizona; Santa Monica, California; Jacksonville, Florida · 8 sites in all
- A Study Comparing the Efficacy of L19TNF+Doxorubicin vs Doxorubicin Alone as First-line Therapy in Patients With Advanced or Metastatic Soft Tissue SarcomaPivotal-lookingStatus unknown
Philogen S.p.A.Industry
NCT04650984 · 102 participants (planned) · Start Nov 29, 2017 · Primary completion Dec 31, 2025
Drug: Onfekafusp alfa; Doxorubicin · For: Soft Tissue Sarcoma
Sites: Bordeaux, France; Dijon, France; Lyon, France · 28 sites in all
- Efficacy and Safety of L19TNF in Previously Treated Patients with Advanced Stage or Metastatic Soft-tissue SarcomaActive, not recruiting
Philogen S.p.A.Industry
NCT04733183 · 98 participants (planned) · Start Aug 28, 2020 · Primary completion Dec 2025
Drug: Dacarbazine; onfekafusp alfa · For: Soft Tissue Sarcoma
Sites: Besançon, France; Bordeaux, France; Clermont-Ferrand, France · 23 sites in all
Philogen S.p.A.Industry
NCT07227870 · 92 participants (planned) · Start Sep 2026 · Primary completion Feb 2031
Drug: L19IL2/L19TNF · For: Locally Advanced Basal Cell Carcinoma
Sites: Tampa, Florida; Atlanta, Georgia; New York, New York · 18 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- [Therapy of melanoma : Current standards and future perspectives].
Hariri I, Hassel JC · Pathologie (Heidelb) 2026
- Emerging immunotherapies in melanoma beyond immune checkpoint inhibitors: Vaccines, intralesional therapies, adoptive cell therapies, and T-cell engagers.
Taglialatela I, Di Corcia L, Boutros A, et al. · Cancer Treat Res Commun 2026
- Neoadjuvant Intralesional Daromun (L19IL2/L19TNF) in Resectable Locally Advanced Melanoma: An Update on the Efficacy and Safety Results of the PIVOTAL Phase III Trial.
Hauschild A, Hassel JC, Ziemer M, et al. · J Clin Oncol 2026
- Targeted TNF Potentiates the Activity of Bispecific T-cell Engagers in Solid Tumors by Turning Cold Tumors Hot.
Thorhallsdottir G, Benz R, Faviana P, et al. · Cancer Immunol Res 2026
- Imaging-guided optimization of biodistribution and antitumor efficacy of L19-based immunocytokines.
Virgilio T, Chahine K, Carreras JG, et al. · Transl Oncol 2026
- Tumor-targeted IL2 promotes specific CD8+ T cells private clonal expansion enhancing lymphoma control.
Virgilio T, Chahine K, Bansal H, et al. · J Exp Clin Cancer Res 2026
Also in development for Glioblastoma
- Anlotinib hydrochlorideAL3818, CatequentenibPhase 312 trials
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Alveolar Soft Part Sarcoma, Metastatic Colorectal Cancer, Endometrial Neoplasms
- VebreltinibPLB1001Phase 36 trials
Avistone Biotechnology Co., Ltd. · Non-Small-Cell Lung Cancer, Glioblastoma, Non-Small Cell Lung Cancer
- VRT106Phase 33 trials
Guangzhou Virotech Pharmaceutical Co., Ltd. · Diffuse Midline Glioma, H3 K27M-Mutant, Diffuse Intrinsic Pontine Glioma, HCC
- INO-9012Phase 24 trials
Geneos Therapeutics · HCC, Glioblastoma, Urothelial Carcinoma
- AL58805Phase 22 trials
Advenchen Pharmaceuticals, LLC. · Endometrial Neoplasms, Soft Tissue Sarcoma (STS), Breast Neoplasms
- AzeliragonPhase 22 trials
Cantex Pharmaceuticals · Glioblastoma
- INO-5401Phase 22 trials
Inovio Pharmaceuticals · Glioblastoma, Urothelial Carcinoma
- MT-125Phase 22 trials
Myosin Therapeutics Inc. · Glioblastoma (GBM), Glioblastoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.